Certificate of Analysis
Third Party Tested
Molecular Profile
Compound
FOXO4-DRI
Batch #
20260605
Formula
C228H388N86O64
Mol Wt
5358 g/mol
CAS
2460055-10-9
latest
ISO 17025
8× Testing
99.80%
Purity
VariantFOXO4-DRI
COA ##13798
Labeled5mg
Validation KeyAXISBIOTECH
Tested08/25/26
Full QC Panel - 8× tested
✓
Purity (HPLC) - 99.80%
✓
Net Peptide Content - 5mg
✓
Identity (HPLC) - FOXO4-DRI
✓
Fentanyl Screen - Not Detected
✓
HPLC Conformity mean - >99%
✓
ISO/IEC 17025 Accredited
Storage Requirements
Stability Information
Lyophilized (powder)
−20°C long-term
2–8°C
Reconstituted
Recommended condition
Light protection
Store away from light
Sealed lyophilized vials are heat-stable; refrigerating or freezing sealed vials is optional. 2–8°C applies to reconstituted solutions.
Peer-Reviewed Literature
Research & References
Research and reference material related to this compound.
01
Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging
02
Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells
03
Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study
04
Hallmarks of cellular senescence
05
The achilles' heel of senescent cells: from transcriptome to senolytic drugs
Safety & Regulatory Compliance Warning
These products are intended solely for laboratory research and analytical applications. They have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not approved for therapeutic use, diagnosis, treatment, or prevention of disease. Under no circumstances should these materials be used for human or animal consumption.
